Facilities

Research and Development Center

Frederick, Maryland

We own an approximately 48,000-square-foot Research and Development Center (RDC) in Frederick, Maryland. This state-of-the-art facility is dedicated to advancing vaccines and antiviral therapies for mpox, smallpox and other infectious diseases. Our RDC also conducts transformative research in the central nervous system (CNS) and immunology drug development. Acquired in October 2021, the main building is constructed as a Biosafety Level (BSL)-2 facility, with some areas designated BSL-3 so that research may be conducted on live SARS-CoV-2 and other pathogens. At full capacity, the RDC can employ 80-100 scientists and technical support staff.